ST. LOUIS--()--Tripos®, a leading provider of drug discovery informatics products and services, today announced that Pfizer has become the latest customer of Benchware® Discovery 360 (D360). The novel license agreement allows Pfizer to deploy the capabilities of D360 to all scientists within its worldwide research sites.
“D360 accelerates drug discovery and development projects by increasing the ability to access, analyze, and share knowledge throughout worldwide discovery teams. Additionally, this agreement incorporates and extends the best of Pfizer’s existing RGate technology.”
As a part of the agreement, Pfizer will license to Tripos certain rights to its internally-developed discovery informatics system, RGate, and Tripos will extend capabilities within D360 to accommodate Pfizer’s unique requirements. D360 will provide a leading technology to Pfizer scientists, while leveraging investment in their legacy system to reduce cost and create a modern, best-of-breed platform for drug discovery and development.
D360 is used by discovery scientists in major pharmaceutical organizations to provide robust data access and analysis capabilities including full-featured, forms-based queries and browsing, a data access dashboard for fast, simple access to data searches, and a wide range of user-requested data analysis functionality.
“Tripos is thrilled that Pfizer has selected D360 as the tool of choice for its worldwide discovery organization,” said Patrick Flanagan, Tripos’ Chief Operating Officer. “D360 accelerates drug discovery and development projects by increasing the ability to access, analyze, and share knowledge throughout worldwide discovery teams. Additionally, this agreement incorporates and extends the best of Pfizer’s existing RGate technology.”
About Benchware Discovery 360
Benchware Discovery 360 removes data access and analysis bottlenecks to improve overall discovery research efficiency by providing high standards of usability and flexibility with data query, presentation and ease-of-access for all research. Designed in close collaboration with research scientists, D360 provides a highly usable information environment with query building, data analysis, visualization, collaboration, and sharing capabilities for all research roles, from chemistry and biology to metabolism and drug safety. D360 is the only commercially-available, enterprise-wide discovery informatics system which provides all the performance, scalability and functionality normally sought in the development of custom, in-house data access and analysis projects.
About Tripos
Tripos, a Certara™ Company, is a global leader in innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Established in 1979, Tripos was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical, food and fragrance industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds intended to become tomorrow’s drugs, foods, flavorings and fragrances. Headquartered in St. Louis, Missouri, Tripos serves more than 1,000 customers in 46 countries.
About Certara
Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos (www.tripos.com) and Pharsight Corporation (www.pharsight.com). Certara reduces the barriers between phases of research to speed discoveries in chemistry, and enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
